替比夫定诱发肌病:FDG PET/CT偶然检出
Telbivudine-Induced Myopathy Incidentally Detected by FDG PET/CT Imaging in a Patient With History of Hepatocellular Carcinoma.
PubMed 文献 · Clin Nucl Med · 2019-01-01
本文报告1例75岁慢性乙肝并肝细胞癌病史男性,FDG PET/CT未见恶性肿瘤特征性高代谢,但腹壁肌肉呈强烈高代谢;停用替比夫定3个月后复查FDG PET/CT,腹壁肌肉代谢恢复正常。提示替比夫定相关肌病可在FDG PET/CT上表现为肌肉高摄取。
要点
- 替比夫定可引起肌病,FDG PET/CT上表现为肌肉高代谢
- 腹壁肌肉强烈高代谢而未见恶性肿瘤特征性摄取时需考虑药物性肌病
- 停药后复查FDG PET/CT肌肉代谢恢复正常,支持该诊断
核心结论
- 替比夫定诱导的肌病可在FDG PET/CT上显示为腹壁肌肉强烈高代谢,停药3个月后复查恢复正常。
研究设计与样本
- 个案报告:1例75岁慢性HBV感染并肝细胞癌病史男性,行FDG PET/CT检查及停用替比夫定3个月后复查。
主要发现
- 首次FDG PET/CT未见恶性肿瘤特征性异常摄取,但腹壁肌肉呈强烈高代谢活性。
- 停用替比夫定3个月后第二次FDG PET/CT显示腹壁肌肉活性正常。
临床怎么用
- 对有替比夫定用药史者,FDG PET/CT见肌肉高代谢而无肿瘤特征性摄取时应考虑药物性肌病并行停药随访。
局限性
- 为单个病例报告,未提供肌酶、肌电图或病理等进一步验证信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myopathy is an adverse effect of telbivudine. We describe a case of telbivudine-induced myopathy visualized on FDG PET/CT in a 75-year-old man with history of chronic HBV infection and hepatocellular carcinoma. FDG PET/CT images demonstrate no abnormal uptake characteristic of hypermetabolic malignancy. However, intense hypermetabolic activity in muscles of the abdominal wall was noted. Three months after telbivudine withdrawal, a second FDG PET/CT showed normal muscle activity in the abdominal wall.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Zou S, Cheng Z, Song S, et al. Telbivudine-Induced Myopathy Incidentally Detected by FDG PET/CT Imaging in a Patient With History of Hepatocellular Carcinoma. Clin Nucl Med. 2019. PMID: 30608913. doi:10.1097/RLU.0000000000002385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。